{"gene":"STAT6","run_date":"2026-06-10T07:46:42","timeline":{"discoveries":[{"year":1994,"finding":"STAT6 (IL-4 Stat) was purified and cloned as an IL-4-induced tyrosine-phosphorylated DNA-binding protein; phosphotyrosine-containing peptides from the intracellular domain of the IL-4 receptor inhibited IL-4 Stat activation, indicating direct receptor coupling; the same functional domain mediates both receptor coupling and dimerization.","method":"Protein purification, gene cloning, inhibitory peptide assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — protein purified and gene cloned, receptor coupling demonstrated by peptide inhibition, replicated across subsequent studies","pmids":["8085155"],"is_preprint":false},{"year":1996,"finding":"Stat6-deficient mice (gene targeting) completely lack IL-4-induced increases in MHC class II antigen and IL-4 receptor surface expression; lymphocytes fail to proliferate in response to IL-4; B cells do not produce IgE; T lymphocytes fail to differentiate into Th2 cells in response to IL-4 or IL-13, establishing Stat6 as essential for IL-4 signaling.","method":"Gene targeting/knockout mouse, cell proliferation assays, flow cytometry, immunization","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — independently generated knockout mouse, multiple orthogonal phenotypic readouts, replicated in parallel by Akira/Kishimoto lab","pmids":["8624821"],"is_preprint":false},{"year":1996,"finding":"Stat6-deficient mice fail to upregulate CD23 and MHC class II on B cells in response to IL-4; IL-4-induced B-cell proliferation and T-cell proliferative responses are abolished; IgE and IgG1 responses after nematode infection are profoundly reduced, confirming Stat6 as central mediator of IL-4 biological responses.","method":"Gene targeting/knockout mouse, flow cytometry, proliferation assays, parasite infection model","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — independent knockout mouse from separate lab, multiple orthogonal phenotypic readouts, replicates findings of Kaplan et al. 1996","pmids":["8602263"],"is_preprint":false},{"year":1996,"finding":"IL-13-mediated macrophage functions (morphologic changes and MHC class II upregulation) are abolished in STAT6-deficient mice, demonstrating that IL-13 signals through the same STAT6 pathway as IL-4.","method":"STAT6-knockout mouse, macrophage functional assays, flow cytometry","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with defined cellular phenotype, establishes shared pathway for IL-4 and IL-13 via STAT6","pmids":["8871614"],"is_preprint":false},{"year":1998,"finding":"STAT6 and NF-κB directly bind each other in vitro and in vivo (GST pulldown and co-immunoprecipitation); tyrosine-phosphorylated STAT6 and NF-κB bind cooperatively to DNA containing both cognate sites and synergistically activate IL-4-induced transcription.","method":"GST pulldown, co-immunoprecipitation, EMSA, luciferase reporter assay","journal":"Molecular and Cellular Biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and in vitro pulldown plus functional reporter assay in two cell systems, single lab","pmids":["9584180"],"is_preprint":false},{"year":1999,"finding":"p300/CBP is required for STAT6-mediated transcriptional induction by IL-4; the STAT6 transactivation domain interacts with a C-terminal region of CBP (aa 1850–2176); E1A represses IL-4-induced STAT6 transcription through p300/CBP sequestration; co-immunoprecipitation confirmed endogenous STAT6–CBP complex.","method":"Two-hybrid assay, co-immunoprecipitation, E1A repression, luciferase reporter, GAL4 fusion assay","journal":"Nucleic Acids Research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, two-hybrid, functional reporter, E1A mutants), single lab","pmids":["10373589"],"is_preprint":false},{"year":2000,"finding":"STAT6 suppresses STAT1-dependent transcription by a mechanism that does not require STAT6 DNA-binding to N4 sites (a H415A mutation that reduces N4 affinity retains full suppression of STAT1/IFNγ-driven transcription); suppression of NF-κB-dependent transcription requires both the STAT6 transactivation domain and STAT6 DNA binding to N4 sites; both mechanisms require the transactivation domain and likely involve sequestration of distinct coactivators.","method":"Transient transfection of STAT6 deletion/point mutants in STAT6-deficient HEK293 cells, luciferase reporter assay","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean STAT6-deficient cell reconstitution with mutagenesis, single lab, single method set","pmids":["10982806"],"is_preprint":false},{"year":2000,"finding":"IL-4 induces phosphorylation of STAT6 on multiple serines within the transactivation domain (residues 719–789); serine phosphorylation does not require tyrosine 641 phosphorylation; PI3K, PKC, and MAPK pathways are not required, suggesting a novel kinase pathway.","method":"Phosphoamino acid analysis, 2D phosphopeptide mapping, STAT6 deletion/point mutants, kinase inhibitors","journal":"Molecular Immunology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — biochemical phosphopeptide mapping with mutagenesis, single lab","pmids":["11164892"],"is_preprint":false},{"year":2001,"finding":"IL-4-induced STAT6 blocks NF-κB DNA binding and nuclear translocation, thereby inhibiting osteoclastogenesis; exogenously added STAT6 protein directly inhibits NF-κB/DNA interaction; IL-4 fails to block osteoclastogenesis in STAT6−/− mice but this is restored by exogenous STAT6.","method":"STAT6-knockout mouse osteoclast differentiation assay, EMSA competition, exogenous STAT6 protein addition","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout rescue experiment plus in vitro EMSA, multiple orthogonal approaches, single lab","pmids":["11390419"],"is_preprint":false},{"year":2002,"finding":"Protein phosphatase 2A (PP2A) inhibition induces serine phosphorylation of STAT6 and severely inhibits STAT6 DNA binding, acting downstream of JAK kinases in IL-4 signaling; PP2A does not affect IL-4-induced tyrosine phosphorylation of JAK1 or STAT6.","method":"PP2A inhibitor (okadaic acid), EMSA, Western blot for phospho-STAT6","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological inhibitor plus biochemical assays, single lab, single method approach","pmids":["12426308"],"is_preprint":false},{"year":2002,"finding":"In mast cells, IL-4 induces nuclear translocation of full-length STAT6 followed by cleavage by a nuclear serine-family protease, generating a C-terminally truncated STAT6 isoform with preferential DNA-binding access; STAT6 chromatin immunoprecipitation identified IL-4-responsive target genes in mast cells including the IL-4 gene itself.","method":"Western blot, nuclear fractionation, serine protease inhibitors, chromatin immunoprecipitation","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — biochemical fractionation and ChIP with protease inhibitor experiments, single lab","pmids":["12244176"],"is_preprint":false},{"year":2004,"finding":"Methylation of STAT6 on Arg27 is required for optimal IL-4-dependent STAT6 tyrosine phosphorylation, nuclear translocation, and DNA-binding activity; Arg27Ala mutant STAT6 and methylation inhibitors markedly diminish all three activities.","method":"STAT6 point mutagenesis (Arg27Ala), methylation inhibitors, Western blot, EMSA, nuclear fractionation","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis plus pharmacological inhibitors with multiple orthogonal readouts, single lab","pmids":["15153491"],"is_preprint":false},{"year":2004,"finding":"PKCζ interacts with and phosphorylates JAK1; PKCζ deficiency ablates Stat6 tyrosine phosphorylation and JAK1 activation in IL-4-stimulated fibroblasts and liver, placing PKCζ upstream of JAK1 in the IL-4/Stat6 pathway.","method":"PKCζ-knockout mouse, co-immunoprecipitation, kinase assay, Western blot for phospho-STAT6/JAK1","journal":"EMBO Journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout combined with co-IP and in vitro kinase assay, multiple orthogonal readouts","pmids":["15526032"],"is_preprint":false},{"year":2005,"finding":"IFN-γ suppresses STAT6 phosphorylation in differentiated Th1 cells by impairing STAT6 recruitment to the phosphorylated IL-4 receptor, without reducing IL-4R expression or JAK1/JAK3 phosphorylation; pulldown with phospho-IL-4R/GST fusion confirmed reduced STAT6 binding in WT vs. IFNGR−/− Th1 cells.","method":"IFNGR-knockout mouse T cells, GST pulldown of STAT6 to phospho-IL-4R, Western blot","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic model with GST pulldown, single lab, single biochemical approach","pmids":["15661890"],"is_preprint":false},{"year":2006,"finding":"RNA helicase A (RHA) is a component of the STAT6 transcription complex; RHA does not directly interact with STAT6 but is bridged through the coactivator p100, forming a ternary STAT6–p100–RHA complex; p100-mediated RHA recruitment enhances STAT6 binding to the IgE promoter and IL-4-induced transcription.","method":"Co-immunoprecipitation, in vitro pulldown, chromatin immunoprecipitation, RNAi knockdown, luciferase reporter","journal":"Nucleic Acids Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, ChIP, RNAi, reporter), single lab","pmids":["16914450"],"is_preprint":false},{"year":2007,"finding":"CoaSt6 (collaborator of STAT6) possesses PARP enzymatic activity that auto-ADP-ribosylates itself and modifies p100; a catalytically inactive CoaSt6 mutant fails to enhance STAT6-mediated transcription; chemical PARP inhibition blocks IL-4-dependent target gene transcription in vivo.","method":"PARP activity assay, CoaSt6 catalytic mutant, PARP inhibitors, luciferase reporter, chromatin immunoprecipitation","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with mutagenesis plus pharmacological inhibition and in-cell reporter, single lab","pmids":["17478423"],"is_preprint":false},{"year":2007,"finding":"IL-4-Stat6 signaling induces expression of tristetraprolin (TTP), an ARE-binding mRNA destabilizing protein, in mast cells; TTP then promotes decay of TNF-α mRNA in an AU-rich element-dependent manner; RNAi depletion of TTP prevents IL-4-mediated TNF-α down-regulation; this effect is absent in Stat6-deficient mice.","method":"Stat6-knockout mouse, RNAi, TNF-α mRNA stability assay, ELISA, peritoneal injection model","journal":"Journal of Experimental Medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout plus RNAi rescue with molecular mechanism (mRNA stability), multiple orthogonal methods","pmids":["14638848"],"is_preprint":false},{"year":2000,"finding":"A gain-of-function STAT6 mutant (STAT6VT) carrying two amino acid changes in the SH2 domain undergoes IL-4-independent tyrosine phosphorylation, dimerization, DNA binding, and transcriptional activation; phosphorylation is mediated by a non-IL-4/non-JAK1/JAK3 kinase in U4A fibroblasts.","method":"STAT6 mutagenesis, transfection in JAK1/JAK3-deficient U4A cells, EMSA, reporter assay, Western blot","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — gain-of-function mutagenesis in defined kinase-deficient cell background, multiple readouts, single lab","pmids":["10747856"],"is_preprint":false},{"year":1999,"finding":"IFN-α activates Stat6 in B cells and induces formation of novel Stat2:Stat6 complexes (including a STAT2–STAT6–p48 ISGF3-like complex); this activation is cell-type specific, occurring predominantly in B cells.","method":"Western blot for phospho-STAT6, co-immunoprecipitation of STAT2:STAT6 complexes, cell line comparison","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and phospho-Western in primary B cells and B cell lines, single lab","pmids":["10490982"],"is_preprint":false},{"year":2000,"finding":"The glucocorticoid receptor (GR) physically associates with STAT6 in T lymphocytes; GC suppress STAT6-dependent transcription without affecting STAT6 DNA binding; STAT6 overexpression enhances IL-4-mediated inhibition of GC-induced MMTV transactivation.","method":"Co-immunoprecipitation, luciferase reporter assay, EMSA in CTLL-2 cells","journal":"FEBS Letters","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP with functional reporter, single lab, single cell line","pmids":["11150515"],"is_preprint":false},{"year":2014,"finding":"The E3 ubiquitin ligase Grail interacts with STAT6, ubiquitinates it, and targets it for degradation, creating a negative feedback loop in Th2 cells; Grail deficiency results in increased STAT6 and IL-4 receptor α expression and enhanced Th2 effector cytokine production; Grail expression itself depends on IL-4/STAT6/GATA3 signaling.","method":"Co-immunoprecipitation, ubiquitination assay, Grail-knockout mouse, Western blot, allergy model","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout plus ubiquitination assay plus Co-IP, multiple orthogonal methods, functional in vivo validation","pmids":["25145352"],"is_preprint":false},{"year":2016,"finding":"Crystal structures of phosphorylated STAT6 core fragment (homodimer) alone and bound to N3 and N4 DNA sites reveal a dramatic conformational change upon DNA binding; H415 in the DNA-binding domain discriminates N4 from N3 sites; H415N mutation decreases N4 affinity and increases N3 affinity both in vitro and in vivo.","method":"X-ray crystallography, molecular dynamics simulation, SAXS, point mutagenesis, DNA binding assay","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with mutagenesis and biophysical validation by three orthogonal methods","pmids":["27803324"],"is_preprint":false},{"year":2014,"finding":"Follicular lymphoma-associated STAT6 mutations (hotspot D419) are activating; they increase transactivation in reporter assays, enhance IL-4-induced target gene expression, and facilitate nuclear residency of STAT6 independently of IL-4-induced Y641 phosphorylation; structural modeling places most mutations at the STAT6–DNA interface.","method":"Luciferase reporter assay, stable STAT6 transfection in lymphoma cell lines, nuclear fractionation, whole-exome sequencing, structural modeling","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple functional assays (reporter, target gene expression, nuclear fractionation) on primary patient material and cell lines","pmids":["25428220"],"is_preprint":false},{"year":2016,"finding":"IL-4-activated STAT6 is required for direct transcriptional repression of a large set of genes during alternative macrophage polarization; repression is associated with decreased lineage-determining TF, p300, and RNA Pol II binding, reduced enhancer RNA, H3K27ac, and chromatin accessibility; STAT6 repressor function is HDAC3-dependent on a subset of genes; STAT6-repressed enhancers overlap the NF-κB p65 cistrome and show decreased LPS responsiveness after IL-4 stimulus.","method":"ChIP-seq, ATAC-seq, enhancer RNA profiling, HDAC3 inhibition, STAT6-knockout macrophages, in vivo polarization","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1 / Strong — genome-wide chromatin assays (ChIP-seq, ATAC-seq) with genetic knockout and pharmacological validation, multiple orthogonal methods","pmids":["29343442"],"is_preprint":false},{"year":2016,"finding":"JAK3-STAT6 pathway activation downstream of IL-4 is required for TET2-dependent DNA demethylation at dendritic-cell-specific loci during monocyte-to-DC differentiation; a constitutively active STAT6 bypasses upstream IL-4 signaling and instructs DC-specific demethylation.","method":"DNA methylome profiling, TET2 knockdown, JAK3 inhibitor, constitutively active STAT6 expression","journal":"Genome Biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide methylome with genetic and pharmacological perturbations plus constitutively active STAT6 rescue, multiple orthogonal methods","pmids":["26758199"],"is_preprint":false},{"year":2019,"finding":"STAT6 deficiency in microglia/macrophages reduces efferocytosis of dead neurons, increases inflammatory gene expression, and enlarges infarct volume after experimental stroke; decreased Arginase 1 (Arg1) expression in STAT6−/− microglia/macrophages is responsible for impaired efferocytosis; adoptive transfer of WT macrophages rescues efferocytosis in STAT6-KO mice.","method":"STAT6-knockout mouse, bone marrow chimeras, microglia/macrophage-neuron co-culture, adoptive macrophage transfer, flow cytometry","journal":"JCI Insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with BM chimera and adoptive transfer rescue, multiple orthogonal in vivo and in vitro experiments","pmids":["31619589"],"is_preprint":false},{"year":2019,"finding":"STAT6 activation downstream of IL-4 or TSG6 signaling drives Gas6 expression in alveolar macrophages; Gas6 expression is required for efferocytosis of apoptotic neutrophils; Gas6-depleted macrophages fail to clear PMNs in LPS-challenged lungs.","method":"In vitro macrophage priming, adoptive macrophage transfer, Gas6 knockdown, STAT6 inhibition, co-culture efferocytosis assay","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic in vitro and in vivo experiments with adoptive transfer and gene knockdown, multiple orthogonal methods","pmids":["31363052"],"is_preprint":false},{"year":2017,"finding":"A stapled helical peptide targeting NCOA1 disrupts the NCOA1/STAT6 protein-protein interaction and represses STAT6-mediated transcription; crystal structure of stapled peptide bound to NCOA1 was solved.","method":"Crystal structure of NCOA1–stapled peptide complex, co-immunoprecipitation, luciferase reporter assay","journal":"Journal of the American Chemical Society","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure plus functional disruption assay, single lab, multiple methods","pmids":["29090910"],"is_preprint":false},{"year":2020,"finding":"TRAF6 stabilizes STAT6 protein by binding STAT6 via its TRAF6 C domain and reducing K48-linked (degradative) ubiquitination of STAT6; TRAF6 promotes K63-linked ubiquitination of STAT6; TRAF6 E3 ligase activity is dispensable for STAT6 stabilization.","method":"Co-immunoprecipitation, ubiquitination assay with K48/K63 linkage-specific antibodies, TRAF6 overexpression/knockout, Western blot","journal":"Molecular Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and ubiquitination assay, single lab, mechanistic follow-up limited","pmids":["33017719"],"is_preprint":false},{"year":2023,"finding":"TRAF3 promotes STAT6 ubiquitination (at K450 and K129 residues) and transcriptional activity; site mutation of K450 abolishes TRAF3-mediated STAT6 activation; TRAF3 deficiency reduces K450 ubiquitination and impairs IL-4-induced M2 macrophage polarization.","method":"Quantitative ubiquitomics, ubiquitination assay, luciferase reporter, STAT6 site mutagenesis, TRAF3-knockout macrophages","journal":"Cell Death and Differentiation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-specific mutagenesis plus quantitative ubiquitomics and reporter assay, multiple orthogonal methods, single lab","pmids":["37474750"],"is_preprint":false},{"year":2022,"finding":"STAT6 competitively binds CREB-binding protein (CBP), inhibiting CBP-mediated P53 acetylation; reduced P53 acetylation transcriptionally restores SLC7A11 expression, thereby suppressing ferroptosis in lung epithelial cells; lung-specific STAT6 depletion exacerbates ferroptosis and ALI.","method":"Co-immunoprecipitation (STAT6–CBP), P53 acetylation assay, ChIP for P53 on SLC7A11 promoter, lung-specific STAT6 knockout mouse, ferrostatin-1 rescue","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and ChIP with genetic knockout, single lab, mechanistic pathway partially established","pmids":["35668064"],"is_preprint":false},{"year":2022,"finding":"STAT6 transcriptionally inhibits PPARα expression through a SIE (sis-inducible element) in the PPARα promoter, reducing fatty acid oxidation-related gene expression and promoting lipid accumulation in renal tubular cells; STAT6 inhibition or tubular-specific depletion restores FAO and attenuates renal fibrosis.","method":"ChIP assay of STAT6 on PPARα promoter, tubular-specific STAT6-knockout mouse, STAT6 inhibitor, gene expression profiling","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP with genetic and pharmacological STAT6 modulation, single lab","pmids":["35046382"],"is_preprint":false},{"year":2022,"finding":"A gain-of-function STAT6 missense variant (p.D419N) increases transcriptional activity independent of IL-4 stimulation, promotes nuclear localization of STAT6 without phosphorylation at baseline, and causes hyperphosphorylation upon IL-4 stimulation; knock-in mice develop spontaneous dermatitis with eosinophil infiltration and elevated IgE.","method":"Luciferase reporter, nuclear fractionation, knock-in mouse model, Western blot","journal":"Journal of Allergy and Clinical Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain-of-function mutagenesis validated in patient cells and knock-in mouse with multiple functional readouts","pmids":["36538978"],"is_preprint":false},{"year":2023,"finding":"A gain-of-function STAT6 mutation (p.E372K in the DNA-binding domain) augments both basal and cytokine-induced STAT6 phosphorylation without altering dephosphorylation kinetics; JAK1/2 inhibitor ruxolitinib reverses the STAT6 hyperresponsiveness, demonstrating the mutation acts upstream of or at the JAK-STAT6 interface.","method":"Western blot of patient lymphocytes, EMSA, immunofluorescence, luciferase assay, JAK inhibitor treatment","journal":"Journal of Allergy and Clinical Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple functional assays in patient cells with pharmacological rescue, orthogonal methods","pmids":["36758835"],"is_preprint":false},{"year":2012,"finding":"IL-4 inhibits melanogenesis in normal human melanocytes through JAK2-STAT6 signaling; IL-4 increases STAT6 phosphorylation and downregulates MITF and dopachrome tautomerase; JAK2 inhibitor AG490 or STAT6 siRNA blocks IL-4-induced melanogenesis suppression.","method":"JAK2 inhibitor, STAT6 siRNA knockdown, Western blot for pSTAT6, gene expression analysis","journal":"Journal of Investigative Dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological inhibitor plus siRNA knockdown, single lab, primary human cells","pmids":["22992805"],"is_preprint":false},{"year":2011,"finding":"IL-4-activated STAT6 is required for Th9 development by repressing T-bet and Foxp3 expression and inducing IRF4; STAT6 activation is independent of TGF-β-induced PU.1 (Sfpi1); these mechanisms define the transcription factor network balancing IL-9 production.","method":"STAT6-knockout mouse Th differentiation assay, retroviral STAT6/IRF4 expression, intracellular cytokine staining","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout with retroviral rescue and multiple transcription factor readouts, single lab","pmids":["22180613"],"is_preprint":false},{"year":2012,"finding":"STAT6-STAT1 axis regulates OC-STAMP and DC-STAMP expression governing macrophage cell-cell fusion (FBGC formation); STAT6 deficiency increases STAT1 activation and inhibits fusion; STAT1 deficiency or co-expression of OC-STAMP/DC-STAMP is sufficient to induce fusion independently of IL-4.","method":"STAT6-knockout and STAT1-knockout mouse macrophage fusion assay, OC-STAMP/DC-STAMP co-expression, Western blot","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic knockouts with defined cellular phenotype, single lab, mechanistic epistasis established","pmids":["22865856"],"is_preprint":false},{"year":2022,"finding":"A germline STAT6 gain-of-function variant (p.Glu377Lys, DNA-binding domain) displays strong nuclear localization preference, increased DNA-binding affinity, and spontaneous transcriptional activity without cytokine stimulation; gastric organoids from the patient show constitutive STAT6 downstream signaling.","method":"EMSA, immunofluorescence, luciferase assay, Western blot, patient-derived gastric organoids","journal":"Journal of Allergy and Clinical Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (EMSA, imaging, reporter, organoids) in patient-derived primary material","pmids":["36216080"],"is_preprint":false},{"year":2022,"finding":"PARP14 is a transcriptional co-activator and direct target of STAT6; activating STAT6 mutations (within the DNA-binding domain) bind the PARP14 promoter (shown by qChIP), increase IL-4-induced transactivation at the PARP14 promoter, and create a self-reinforcing STAT6–PARP14 regulatory circuit; PARP14 knockdown or PARP inhibition abrogates STAT6-mutant gain-of-function.","method":"qChIP of STAT6 on PARP14 promoter, luciferase reporter, PARP14 siRNA, PARP inhibitor, RNA sequencing","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP, reporter, and functional rescue experiments with multiple orthogonal methods, single lab","pmids":["35851155"],"is_preprint":false}],"current_model":"STAT6 is a latent cytoplasmic transcription factor activated primarily by IL-4 and IL-13: upon receptor engagement, JAK kinases (including JAK1 and JAK3) phosphorylate STAT6 on Tyr641, a step facilitated by prior Arg27 methylation and regulated by PKCζ-dependent JAK1 phosphorylation, PP2A, and IFN-γ-mediated impairment of STAT6 recruitment to the IL-4 receptor; activated STAT6 dimerizes, translocates to the nucleus (a step that can also occur via constitutively activating mutations in the SH2 or DNA-binding domains), and binds N4-type GAS elements—preferentially over N3 sites through a unique H415 residue—as revealed by crystal structures; in the nucleus STAT6 recruits coactivators p300/CBP (at a distinct CBP C-terminal region), NCOA1, the p100–RNA helicase A complex, and the PARP-active cofactor CoaSt6/PARP14 to drive transcription of Th2-associated genes (including CCL17, CCL22, Gas6, Arg1, IL-31RA, TARC, and eotaxin-1); STAT6 simultaneously represses inflammatory enhancers in an HDAC3-dependent manner, inhibits NF-κB DNA binding, and suppresses PPARα-driven fatty acid oxidation via a SIE element; its activity is negatively regulated by the E3 ligase Grail (which ubiquitinates STAT6 for degradation) and positively stabilized by TRAF6 (which reduces K48-ubiquitination) and TRAF3 (which promotes activating K450 ubiquitination); in mast cells a nuclear serine protease cleaves full-length STAT6 to a truncated isoform; and somatic or germline gain-of-function mutations in the DNA-binding domain cause constitutive nuclear residency and ligand-independent transcriptional activation, driving allergic disease and lymphomagenesis."},"narrative":{"mechanistic_narrative":"STAT6 is a latent cytoplasmic transcription factor that serves as the central effector of IL-4 and IL-13 signaling, driving Th2-associated gene programs, alternative macrophage polarization, and humoral responses [PMID:8085155, PMID:8624821, PMID:8871614]. It was cloned as an IL-4-induced tyrosine-phosphorylated DNA-binding protein whose intracellular receptor coupling and dimerization map to the same functional domain [PMID:8085155], and genetic ablation in mice abolishes IL-4/IL-13-driven CD23 and MHC class II upregulation, B-cell proliferation, IgE/IgG1 class switching, Th2 differentiation, and IL-13-mediated macrophage activation [PMID:8624821, PMID:8602263, PMID:8871614]. Receptor-proximal activation requires JAK1, which is itself phosphorylated by upstream PKCζ, and is potentiated by Arg27 methylation that licenses optimal tyrosine phosphorylation, nuclear translocation, and DNA binding [PMID:15153491, PMID:15526032]. Activated STAT6 dimerizes and engages N4-type GAS elements with preference over N3 sites through a discriminating H415 residue, as resolved by crystal structures showing a large DNA-binding conformational change [PMID:27803324]. In the nucleus STAT6 recruits coactivators p300/CBP, NCOA1, the bridging p100–RNA helicase A complex, and the PARP-active cofactor CoaSt6/PARP14 to activate target genes, while it also represses inflammatory enhancers overlapping the NF-κB p65 cistrome in an HDAC3-dependent manner and directly blocks NF-κB DNA binding [PMID:10373589, PMID:16914450, PMID:17478423, PMID:29343442, PMID:11390419]. Through these outputs STAT6 instructs Arg1- and Gas6-dependent macrophage efferocytosis, monocyte-to-DC demethylation, and Th9 differentiation [PMID:31619589, PMID:31363052, PMID:26758199, PMID:22180613]. STAT6 abundance and activity are tuned by ubiquitination: the E3 ligase Grail targets it for degradation, whereas TRAF6 reduces K48-linked degradative ubiquitination and TRAF3 promotes activating K450 ubiquitination [PMID:25145352, PMID:33017719, PMID:37474750]. Gain-of-function mutations in the SH2 and DNA-binding domains confer ligand-independent nuclear residency and constitutive transcription, causing germline allergic disease with eosinophilia and elevated IgE and driving follicular lymphomagenesis, with mutant activity sustained by a self-reinforcing STAT6–PARP14 circuit [PMID:10747856, PMID:25428220, PMID:36538978, PMID:36216080, PMID:35851155].","teleology":[{"year":1994,"claim":"Established the molecular identity of the IL-4-induced DNA-binding activity, defining STAT6 as a receptor-coupled transcription factor and the entry point of the entire pathway.","evidence":"Protein purification, gene cloning, and phosphopeptide inhibition of receptor coupling","pmids":["8085155"],"confidence":"High","gaps":["Did not identify activating kinases","No nuclear target genes defined at this stage"]},{"year":1996,"claim":"Defined STAT6 as genetically essential and non-redundant for IL-4 and IL-13 biology, converting a biochemical activity into a defined physiological pathway.","evidence":"Independent STAT6-knockout mice with B-cell, T-cell, IgE, Th2, and macrophage readouts","pmids":["8624821","8602263","8871614"],"confidence":"High","gaps":["Knockouts did not resolve direct vs indirect target genes","Mechanism of IL-4/IL-13 pathway convergence not molecularly dissected"]},{"year":2000,"claim":"Showed STAT6 acts not only as an activator but as a repressor of STAT1/IFNγ and NF-κB transcription, and that gain-of-function SH2 mutants activate independently of IL-4/JAK1/JAK3, foreshadowing constitutive disease alleles.","evidence":"Mutant reconstitution in STAT6-deficient and JAK-deficient cells with reporter and EMSA assays","pmids":["10982806","10747856","11150515"],"confidence":"Medium","gaps":["Identity of the non-JAK kinase phosphorylating STAT6VT not determined","Coactivator-sequestration model of repression not directly proven"]},{"year":2001,"claim":"Demonstrated direct STAT6–NF-κB cross-regulation, with STAT6 protein blocking NF-κB DNA binding and nuclear translocation to suppress osteoclastogenesis, extending STAT6 beyond Th2 gene induction.","evidence":"Reciprocal Co-IP, EMSA cooperativity/competition, and knockout rescue with exogenous STAT6","pmids":["9584180","11390419"],"confidence":"High","gaps":["Structural basis of STAT6–NF-κB contact not resolved","In vivo balance of cooperative vs antagonistic NF-κB outcomes unclear"]},{"year":2004,"claim":"Mapped upstream and post-translational control of activation, placing PKCζ above JAK1 and identifying Arg27 methylation as a licensing modification for tyrosine phosphorylation and nuclear entry.","evidence":"PKCζ-knockout mice with kinase assays, and Arg27Ala mutagenesis with methylation inhibitors","pmids":["15526032","15153491"],"confidence":"High","gaps":["Arg27 methyltransferase not identified","Quantitative ordering of methylation relative to receptor engagement not established"]},{"year":2006,"claim":"Resolved the composition of the STAT6 nuclear coactivator complex, showing RNA helicase A is recruited via the p100 bridge and enhances IgE promoter occupancy and transcription.","evidence":"Co-IP, in vitro pulldown, ChIP, RNAi, and reporter assays","pmids":["16914450","10373589"],"confidence":"Medium","gaps":["Stoichiometry of the STAT6–p100–RHA complex undefined","Genome-wide scope of RHA dependence not established"]},{"year":2007,"claim":"Identified an enzymatic coactivator arm, CoaSt6/PARP14 ADP-ribosylation activity, required for STAT6-driven transcription, linking a catalytic modification to target gene output.","evidence":"PARP activity assay with catalytic-dead mutant, PARP inhibitors, reporter, and ChIP","pmids":["17478423"],"confidence":"High","gaps":["Direct ADP-ribosylation targets within the complex beyond p100 not fully mapped","In vivo relevance to physiological Th2 genes only partially defined"]},{"year":2016,"claim":"Provided the structural mechanism of DNA-site selectivity, showing H415 discriminates N4 from N3 GAS elements through a major conformational change on binding.","evidence":"X-ray crystallography of phospho-STAT6 dimer with N3/N4 DNA, SAXS, MD, and H415 mutagenesis","pmids":["27803324"],"confidence":"High","gaps":["Full-length STAT6 (with transactivation and N-domains) not crystallized","Structure of coactivator-bound complexes not solved"]},{"year":2018,"claim":"Established STAT6 as a genome-scale direct transcriptional repressor in alternatively activated macrophages, acting through HDAC3 and decommissioning NF-κB-overlapping inflammatory enhancers.","evidence":"ChIP-seq, ATAC-seq, eRNA profiling, HDAC3 inhibition, and STAT6-knockout macrophages","pmids":["29343442"],"confidence":"High","gaps":["Mechanism of HDAC3 recruitment by STAT6 not defined","Determinants of activated vs repressed locus choice unresolved"]},{"year":2019,"claim":"Connected STAT6 transcriptional output to functional macrophage programs, showing Arg1- and Gas6-dependent efferocytosis that limits tissue injury.","evidence":"STAT6-knockout mice, bone marrow chimeras, adoptive transfer, gene knockdown, and co-culture efferocytosis","pmids":["31619589","31363052","26758199","22180613"],"confidence":"High","gaps":["Direct vs indirect STAT6 control of Arg1/Gas6 loci not fully dissected in every tissue","Crosstalk with other AAM transcription factors incompletely mapped"]},{"year":2020,"claim":"Defined ubiquitin-based control of STAT6 stability and activity, with Grail driving degradation, TRAF6 antagonizing degradative K48 chains, and TRAF3 installing activating K450 ubiquitin.","evidence":"Co-IP, linkage-specific ubiquitination assays, site mutagenesis, and E3-ligase knockout macrophages/mice","pmids":["25145352","33017719","37474750"],"confidence":"High","gaps":["Deubiquitinases counteracting these E3s not identified","Interplay/ordering of competing ubiquitin marks on the same molecule unresolved"]},{"year":2023,"claim":"Established gain-of-function STAT6 alleles as drivers of human disease, with SH2 and DNA-binding-domain mutations conferring ligand-independent nuclear residency and constitutive transcription in allergy and lymphoma, sustained by a STAT6–PARP14 feed-forward loop and reversible by JAK inhibition.","evidence":"Reporter assays, nuclear fractionation, EMSA, patient cells/organoids, knock-in mice, qChIP, PARP14 knockdown, and ruxolitinib treatment","pmids":["25428220","36538978","36758835","36216080","35851155"],"confidence":"High","gaps":["Genotype-phenotype determinants separating allergic vs oncogenic outcomes unclear","Whether PARP14 circuit is therapeutically tractable in patients not established"]},{"year":null,"claim":"The kinase responsible for ligand-independent phosphorylation of STAT6 gain-of-function mutants and the identity of the Arg27 methyltransferase and STAT6-cleaving mast-cell protease remain undefined.","evidence":"Not yet addressed in the available corpus","pmids":[],"confidence":"Low","gaps":["Non-JAK kinase acting on constitutive STAT6 mutants not identified","Physiological role of the truncated mast-cell STAT6 isoform unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,22,23,38]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,21,37]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[21]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,30]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,11]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[11,22,32,37]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,12,21]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,14,23,38]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,2,3,23,35]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[22,32,37]}],"complexes":["STAT6–p100–RNA helicase A complex","STAT2–STAT6–p48 (ISGF3-like) complex"],"partners":["CBP/P300","NCOA1","PARP14","NFKB1","JAK1","TRAF6","TRAF3","RBCK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P42226","full_name":"Signal transducer and activator of transcription 6","aliases":["IL-4 Stat"],"length_aa":847,"mass_kda":94.1,"function":"Carries out a dual function: signal transduction and activation of transcription. Involved in IL4/interleukin-4- and IL3/interleukin-3-mediated signaling","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P42226/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/STAT6","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/STAT6","total_profiled":1310},"omim":[{"mim_id":"620532","title":"HYPER-IgE SYNDROME 6, AUTOSOMAL DOMINANT, WITH RECURRENT INFECTIONS; HIES6","url":"https://www.omim.org/entry/620532"},{"mim_id":"620480","title":"TRIPARTITE MOTIF FAMILY-LIKE PROTEIN 2; TRIML2","url":"https://www.omim.org/entry/620480"},{"mim_id":"620432","title":"OSTEOCLAST STIMULATORY TRANSMEMBRANE PROTEIN; OCSTAMP","url":"https://www.omim.org/entry/620432"},{"mim_id":"612374","title":"STIMULATOR OF INTERFERON RESPONSE cGAMP INTERACTOR 1; STING1","url":"https://www.omim.org/entry/612374"},{"mim_id":"610028","title":"POLY(ADP-RIBOSE) POLYMERASE FAMILY, MEMBER 14; PARP14","url":"https://www.omim.org/entry/610028"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Connecting piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/STAT6"},"hgnc":{"alias_symbol":["D12S1644","IL-4-STAT"],"prev_symbol":[]},"alphafold":{"accession":"P42226","domains":[{"cath_id":"1.10.532.10","chopping":"2-118","consensus_level":"medium","plddt":88.0283,"start":2,"end":118},{"cath_id":"2.60.40.630","chopping":"279-326_336-417","consensus_level":"high","plddt":89.4992,"start":279,"end":417},{"cath_id":"3.30.505.10","chopping":"446-629","consensus_level":"high","plddt":95.2121,"start":446,"end":629},{"cath_id":"1.20.58","chopping":"119-158_176-271","consensus_level":"medium","plddt":91.3504,"start":119,"end":271}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P42226","model_url":"https://alphafold.ebi.ac.uk/files/AF-P42226-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P42226-F1-predicted_aligned_error_v6.png","plddt_mean":76.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=STAT6","jax_strain_url":"https://www.jax.org/strain/search?query=STAT6"},"sequence":{"accession":"P42226","fasta_url":"https://rest.uniprot.org/uniprotkb/P42226.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P42226/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P42226"}},"corpus_meta":[{"pmid":"8624821","id":"PMC_8624821","title":"Stat6 is required for mediating responses to IL-4 and for development of Th2 cells.","date":"1996","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8624821","citation_count":1274,"is_preprint":false},{"pmid":"8602263","id":"PMC_8602263","title":"Essential role of Stat6 in IL-4 signalling.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8602263","citation_count":1240,"is_preprint":false},{"pmid":"8085155","id":"PMC_8085155","title":"An interleukin-4-induced transcription factor: IL-4 Stat.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8085155","citation_count":776,"is_preprint":false},{"pmid":"10661403","id":"PMC_10661403","title":"Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment.","date":"2000","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10661403","citation_count":528,"is_preprint":false},{"pmid":"18166499","id":"PMC_18166499","title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6.","date":"2007","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/18166499","citation_count":416,"is_preprint":false},{"pmid":"31619589","id":"PMC_31619589","title":"STAT6/Arg1 promotes microglia/macrophage efferocytosis and inflammation resolution in stroke mice.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31619589","citation_count":261,"is_preprint":false},{"pmid":"16540365","id":"PMC_16540365","title":"Signaling mechanisms, interaction partners, and target genes of STAT6.","date":"2006","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16540365","citation_count":248,"is_preprint":false},{"pmid":"10851056","id":"PMC_10851056","title":"The biology of Stat4 and Stat6.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10851056","citation_count":232,"is_preprint":false},{"pmid":"21149710","id":"PMC_21149710","title":"IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21149710","citation_count":213,"is_preprint":false},{"pmid":"29343442","id":"PMC_29343442","title":"The Transcription Factor STAT6 Mediates Direct Repression of Inflammatory Enhancers and Limits Activation of Alternatively Polarized Macrophages.","date":"2018","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29343442","citation_count":207,"is_preprint":false},{"pmid":"22180613","id":"PMC_22180613","title":"STAT6-dependent regulation of Th9 development.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22180613","citation_count":190,"is_preprint":false},{"pmid":"8871614","id":"PMC_8871614","title":"Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8871614","citation_count":183,"is_preprint":false},{"pmid":"9584180","id":"PMC_9584180","title":"Interaction of stat6 and NF-kappaB: direct association and synergistic activation of interleukin-4-induced transcription.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9584180","citation_count":169,"is_preprint":false},{"pmid":"35668064","id":"PMC_35668064","title":"STAT6 inhibits ferroptosis and alleviates acute lung injury via regulating P53/SLC7A11 pathway.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35668064","citation_count":164,"is_preprint":false},{"pmid":"11390419","id":"PMC_11390419","title":"IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.","date":"2001","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11390419","citation_count":157,"is_preprint":false},{"pmid":"25934862","id":"PMC_25934862","title":"Transcription factors STAT6 and KLF4 implement macrophage polarization via the dual catalytic powers of MCPIP.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25934862","citation_count":154,"is_preprint":false},{"pmid":"28615615","id":"PMC_28615615","title":"STAT6 Upregulation Promotes M2 Macrophage Polarization to Suppress Atherosclerosis.","date":"2017","source":"Medical science monitor basic research","url":"https://pubmed.ncbi.nlm.nih.gov/28615615","citation_count":146,"is_preprint":false},{"pmid":"24416647","id":"PMC_24416647","title":"STAT6 and lung inflammation.","date":"2013","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24416647","citation_count":123,"is_preprint":false},{"pmid":"31363052","id":"PMC_31363052","title":"STAT6 induces expression of Gas6 in macrophages to clear apoptotic neutrophils and resolve inflammation.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31363052","citation_count":116,"is_preprint":false},{"pmid":"25428220","id":"PMC_25428220","title":"Activating STAT6 mutations in follicular lymphoma.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25428220","citation_count":111,"is_preprint":false},{"pmid":"16322752","id":"PMC_16322752","title":"PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways.","date":"2006","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/16322752","citation_count":108,"is_preprint":false},{"pmid":"10373589","id":"PMC_10373589","title":"p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6.","date":"1999","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/10373589","citation_count":107,"is_preprint":false},{"pmid":"26758199","id":"PMC_26758199","title":"IL-4 orchestrates STAT6-mediated DNA demethylation leading to dendritic cell differentiation.","date":"2016","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/26758199","citation_count":101,"is_preprint":false},{"pmid":"26032813","id":"PMC_26032813","title":"JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis.","date":"2015","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/26032813","citation_count":99,"is_preprint":false},{"pmid":"11254707","id":"PMC_11254707","title":"STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alpha-induced fibroblasts.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11254707","citation_count":97,"is_preprint":false},{"pmid":"9181473","id":"PMC_9181473","title":"STAT6: its role in interleukin 4-mediated biological functions.","date":"1997","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/9181473","citation_count":97,"is_preprint":false},{"pmid":"15585884","id":"PMC_15585884","title":"Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN-gamma.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15585884","citation_count":92,"is_preprint":false},{"pmid":"10982806","id":"PMC_10982806","title":"Interleukin-4/STAT6 represses STAT1 and NF-kappa B-dependent transcription through distinct mechanisms.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10982806","citation_count":91,"is_preprint":false},{"pmid":"14500660","id":"PMC_14500660","title":"Identification of novel IL-4/Stat6-regulated genes in T lymphocytes.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14500660","citation_count":86,"is_preprint":false},{"pmid":"33991851","id":"PMC_33991851","title":"STAT6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology.","date":"2021","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/33991851","citation_count":84,"is_preprint":false},{"pmid":"17478423","id":"PMC_17478423","title":"Collaborator of Stat6 (CoaSt6)-associated poly(ADP-ribose) polymerase activity modulates Stat6-dependent gene transcription.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17478423","citation_count":79,"is_preprint":false},{"pmid":"22992805","id":"PMC_22992805","title":"IL-4 inhibits the melanogenesis of normal human melanocytes through the JAK2-STAT6 signaling pathway.","date":"2012","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22992805","citation_count":78,"is_preprint":false},{"pmid":"16810739","id":"PMC_16810739","title":"IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16810739","citation_count":77,"is_preprint":false},{"pmid":"27113293","id":"PMC_27113293","title":"IL-13 mediates collagen deposition via STAT6 and microRNA-135b: a role for epigenetics.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27113293","citation_count":73,"is_preprint":false},{"pmid":"10490982","id":"PMC_10490982","title":"IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10490982","citation_count":72,"is_preprint":false},{"pmid":"26208975","id":"PMC_26208975","title":"Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis.","date":"2015","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/26208975","citation_count":72,"is_preprint":false},{"pmid":"18294957","id":"PMC_18294957","title":"IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18294957","citation_count":71,"is_preprint":false},{"pmid":"37474750","id":"PMC_37474750","title":"TRAF3/STAT6 axis regulates macrophage polarization and tumor progression.","date":"2023","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/37474750","citation_count":70,"is_preprint":false},{"pmid":"12082548","id":"PMC_12082548","title":"STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells.","date":"2002","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12082548","citation_count":63,"is_preprint":false},{"pmid":"19494273","id":"PMC_19494273","title":"Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19494273","citation_count":62,"is_preprint":false},{"pmid":"24777733","id":"PMC_24777733","title":"B-cell-intrinsic STAT6 signaling controls germinal center formation.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24777733","citation_count":61,"is_preprint":false},{"pmid":"21321603","id":"PMC_21321603","title":"Cisplatin ototoxicity involves cytokines and STAT6 signaling network.","date":"2011","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21321603","citation_count":61,"is_preprint":false},{"pmid":"17785825","id":"PMC_17785825","title":"Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17785825","citation_count":60,"is_preprint":false},{"pmid":"14638848","id":"PMC_14638848","title":"IL-4-Stat6 signaling induces tristetraprolin expression and inhibits TNF-alpha production in mast cells.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14638848","citation_count":60,"is_preprint":false},{"pmid":"16213149","id":"PMC_16213149","title":"The role of constitutively active Stat6 in leukemia and lymphoma.","date":"2005","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/16213149","citation_count":58,"is_preprint":false},{"pmid":"26883114","id":"PMC_26883114","title":"NAB2-STAT6 Gene Fusion in Meningeal Hemangiopericytoma and Solitary Fibrous Tumor.","date":"2016","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26883114","citation_count":57,"is_preprint":false},{"pmid":"27803324","id":"PMC_27803324","title":"Structural basis for DNA recognition by STAT6.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27803324","citation_count":57,"is_preprint":false},{"pmid":"36538978","id":"PMC_36538978","title":"STAT6 gain-of-function variant exacerbates multiple allergic symptoms.","date":"2022","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36538978","citation_count":54,"is_preprint":false},{"pmid":"10747856","id":"PMC_10747856","title":"A gain-of-function mutation in STAT6.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10747856","citation_count":53,"is_preprint":false},{"pmid":"15153491","id":"PMC_15153491","title":"Methylation of STAT6 modulates STAT6 phosphorylation, nuclear translocation, and DNA-binding activity.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15153491","citation_count":53,"is_preprint":false},{"pmid":"36758835","id":"PMC_36758835","title":"Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36758835","citation_count":52,"is_preprint":false},{"pmid":"33745702","id":"PMC_33745702","title":"Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour.","date":"2021","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33745702","citation_count":49,"is_preprint":false},{"pmid":"36757802","id":"PMC_36757802","title":"IL-13RA2 downregulation in fibroblasts promotes keloid fibrosis via JAK/STAT6 activation.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36757802","citation_count":48,"is_preprint":false},{"pmid":"36216080","id":"PMC_36216080","title":"A germline STAT6 gain-of-function variant is associated with early-onset allergies.","date":"2022","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36216080","citation_count":48,"is_preprint":false},{"pmid":"35046382","id":"PMC_35046382","title":"STAT6 contributes to renal fibrosis by modulating PPARα-mediated tubular fatty acid oxidation.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35046382","citation_count":48,"is_preprint":false},{"pmid":"25145352","id":"PMC_25145352","title":"Grail controls Th2 cell development by targeting STAT6 for degradation.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25145352","citation_count":48,"is_preprint":false},{"pmid":"11164892","id":"PMC_11164892","title":"IL-4 induces serine phosphorylation of the STAT6 transactivation domain in B lymphocytes.","date":"2000","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11164892","citation_count":48,"is_preprint":false},{"pmid":"9796920","id":"PMC_9796920","title":"STAT6, NF-kappaB and C/EBP in CD23 expression and IgE production.","date":"1998","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9796920","citation_count":47,"is_preprint":false},{"pmid":"23844087","id":"PMC_23844087","title":"TLR3-induced placental miR-210 down-regulates the STAT6/interleukin-4 pathway.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23844087","citation_count":47,"is_preprint":false},{"pmid":"10586046","id":"PMC_10586046","title":"Stat6-dependent and -independent pathways for IL-4 production.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10586046","citation_count":46,"is_preprint":false},{"pmid":"15526032","id":"PMC_15526032","title":"Crosstalk between PKCzeta and the IL4/Stat6 pathway during T-cell-mediated hepatitis.","date":"2004","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15526032","citation_count":46,"is_preprint":false},{"pmid":"11150515","id":"PMC_11150515","title":"The glucocorticoid receptor and STAT6 physically and functionally interact in T-lymphocytes.","date":"2000","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11150515","citation_count":46,"is_preprint":false},{"pmid":"31041750","id":"PMC_31041750","title":"Analysis of IL-4/STAT6 Signaling in Macrophages.","date":"2019","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/31041750","citation_count":42,"is_preprint":false},{"pmid":"25847241","id":"PMC_25847241","title":"Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25847241","citation_count":40,"is_preprint":false},{"pmid":"17371990","id":"PMC_17371990","title":"CCL23 expression is induced by IL-4 in a STAT6-dependent fashion.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17371990","citation_count":39,"is_preprint":false},{"pmid":"21751242","id":"PMC_21751242","title":"Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis.","date":"2011","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21751242","citation_count":38,"is_preprint":false},{"pmid":"37316763","id":"PMC_37316763","title":"Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with Lymphoma.","date":"2023","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37316763","citation_count":36,"is_preprint":false},{"pmid":"21595984","id":"PMC_21595984","title":"STAT6 expression in glioblastoma promotes invasive growth.","date":"2011","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21595984","citation_count":36,"is_preprint":false},{"pmid":"22865856","id":"PMC_22865856","title":"An essential role for STAT6-STAT1 protein signaling in promoting macrophage cell-cell fusion.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22865856","citation_count":36,"is_preprint":false},{"pmid":"30665041","id":"PMC_30665041","title":"IL-37 attenuates allergic process via STAT6/STAT3 pathways in murine allergic rhinitis.","date":"2019","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30665041","citation_count":36,"is_preprint":false},{"pmid":"9845517","id":"PMC_9845517","title":"Stat6 inhibits human interleukin-4 promoter activity in T cells.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9845517","citation_count":36,"is_preprint":false},{"pmid":"15470039","id":"PMC_15470039","title":"STAT6-dependent differentiation and production of IL-5 and IL-13 in murine NK2 cells.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15470039","citation_count":35,"is_preprint":false},{"pmid":"10725752","id":"PMC_10725752","title":"Activation of the IL-4 STAT pathway in rheumatoid synovium.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10725752","citation_count":34,"is_preprint":false},{"pmid":"10229091","id":"PMC_10229091","title":"STAT6-independent production of IL-4 by mast cells.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10229091","citation_count":34,"is_preprint":false},{"pmid":"11997017","id":"PMC_11997017","title":"Corticosteroid inhibits IL-4 signaling through down-regulation of IL-4 receptor and STAT6 activity.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11997017","citation_count":34,"is_preprint":false},{"pmid":"37941008","id":"PMC_37941008","title":"Efferocytosis is restricted by axon guidance molecule EphA4 via ERK/Stat6/MERTK signaling following brain injury.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37941008","citation_count":33,"is_preprint":false},{"pmid":"11067913","id":"PMC_11067913","title":"Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11067913","citation_count":33,"is_preprint":false},{"pmid":"33652833","id":"PMC_33652833","title":"STAT6 Signaling Mediates PPARγ Activation and Resolution of Acute Sterile Inflammation in Mice.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33652833","citation_count":31,"is_preprint":false},{"pmid":"33153718","id":"PMC_33153718","title":"TRPM7 modulates macrophage polarization by STAT1/STAT6 pathways in RAW264.7 cells.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33153718","citation_count":30,"is_preprint":false},{"pmid":"12426308","id":"PMC_12426308","title":"Protein phosphatase 2A (PP2A) regulates interleukin-4-mediated STAT6 signaling.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12426308","citation_count":29,"is_preprint":false},{"pmid":"16914450","id":"PMC_16914450","title":"Characterization of RNA helicase A as component of STAT6-dependent enhanceosome.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16914450","citation_count":29,"is_preprint":false},{"pmid":"39188021","id":"PMC_39188021","title":"STAT4 and STAT6, their role in cellular and humoral immunity and in diverse human diseases.","date":"2024","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39188021","citation_count":27,"is_preprint":false},{"pmid":"33017719","id":"PMC_33017719","title":"TRAF6 promotes IL-4-induced M2 macrophage activation by stabilizing STAT6.","date":"2020","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33017719","citation_count":27,"is_preprint":false},{"pmid":"29090910","id":"PMC_29090910","title":"Targeted Inhibition of the NCOA1/STAT6 Protein-Protein Interaction.","date":"2017","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/29090910","citation_count":27,"is_preprint":false},{"pmid":"12244176","id":"PMC_12244176","title":"IL-4 induces the proteolytic processing of mast cell STAT6.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12244176","citation_count":27,"is_preprint":false},{"pmid":"20608912","id":"PMC_20608912","title":"Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis.","date":"2011","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/20608912","citation_count":27,"is_preprint":false},{"pmid":"14593499","id":"PMC_14593499","title":"Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease.","date":"2003","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/14593499","citation_count":27,"is_preprint":false},{"pmid":"14636897","id":"PMC_14636897","title":"IL-4-dependent CD86 expression requires JAK/STAT6 activation and is negatively regulated by PKCdelta.","date":"2004","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/14636897","citation_count":26,"is_preprint":false},{"pmid":"15661890","id":"PMC_15661890","title":"IFN-gamma suppresses STAT6 phosphorylation by inhibiting its recruitment to the IL-4 receptor.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15661890","citation_count":26,"is_preprint":false},{"pmid":"39107960","id":"PMC_39107960","title":"S100A9 deletion in microglia/macrophages ameliorates brain injury through the STAT6/PPARγ pathway in ischemic stroke.","date":"2024","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/39107960","citation_count":25,"is_preprint":false},{"pmid":"33662403","id":"PMC_33662403","title":"The roles of STAT6 in regulating B cell fate, activation, and function.","date":"2021","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33662403","citation_count":25,"is_preprint":false},{"pmid":"32360783","id":"PMC_32360783","title":"Interleukin-4 stimulates lipogenesis in meibocytes by activating the STAT6/PPARγ signaling pathway.","date":"2020","source":"The ocular surface","url":"https://pubmed.ncbi.nlm.nih.gov/32360783","citation_count":25,"is_preprint":false},{"pmid":"33264064","id":"PMC_33264064","title":"Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6.","date":"2021","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33264064","citation_count":25,"is_preprint":false},{"pmid":"22045870","id":"PMC_22045870","title":"Transcriptional activation of the IL31 gene by NFAT and STAT6.","date":"2011","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22045870","citation_count":24,"is_preprint":false},{"pmid":"39701329","id":"PMC_39701329","title":"Irisin reprograms microglia through activation of STAT6 and prevents cognitive dysfunction after surgery in mice.","date":"2024","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/39701329","citation_count":23,"is_preprint":false},{"pmid":"35327639","id":"PMC_35327639","title":"Inhibition of STAT6 Activation by AS1517499 Inhibits Expression and Activity of PPARγ in Macrophages to Resolve Acute Inflammation in Mice.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/35327639","citation_count":23,"is_preprint":false},{"pmid":"35851155","id":"PMC_35851155","title":"PARP14 is a novel target in STAT6 mutant follicular lymphoma.","date":"2022","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/35851155","citation_count":22,"is_preprint":false},{"pmid":"37741355","id":"PMC_37741355","title":"Electroacupuncture Alleviates Neuroinflammation by Regulating Microglia Polarization via STAT6/PPARγ in Ischemic Stroke Rats.","date":"2023","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37741355","citation_count":21,"is_preprint":false},{"pmid":"31822802","id":"PMC_31822802","title":"Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities.","date":"2019","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/31822802","citation_count":21,"is_preprint":false},{"pmid":"11944890","id":"PMC_11944890","title":"Phytochemical inhibition of interleukin-4-activated Stat6 and expression of VCAM-1.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11944890","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49388,"output_tokens":9377,"usd":0.144409,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19724,"output_tokens":4633,"usd":0.107222,"stage2_stop_reason":"end_turn"},"total_usd":0.251631,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"STAT6 (IL-4 Stat) was purified and cloned as an IL-4-induced tyrosine-phosphorylated DNA-binding protein; phosphotyrosine-containing peptides from the intracellular domain of the IL-4 receptor inhibited IL-4 Stat activation, indicating direct receptor coupling; the same functional domain mediates both receptor coupling and dimerization.\",\n      \"method\": \"Protein purification, gene cloning, inhibitory peptide assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — protein purified and gene cloned, receptor coupling demonstrated by peptide inhibition, replicated across subsequent studies\",\n      \"pmids\": [\"8085155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Stat6-deficient mice (gene targeting) completely lack IL-4-induced increases in MHC class II antigen and IL-4 receptor surface expression; lymphocytes fail to proliferate in response to IL-4; B cells do not produce IgE; T lymphocytes fail to differentiate into Th2 cells in response to IL-4 or IL-13, establishing Stat6 as essential for IL-4 signaling.\",\n      \"method\": \"Gene targeting/knockout mouse, cell proliferation assays, flow cytometry, immunization\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — independently generated knockout mouse, multiple orthogonal phenotypic readouts, replicated in parallel by Akira/Kishimoto lab\",\n      \"pmids\": [\"8624821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Stat6-deficient mice fail to upregulate CD23 and MHC class II on B cells in response to IL-4; IL-4-induced B-cell proliferation and T-cell proliferative responses are abolished; IgE and IgG1 responses after nematode infection are profoundly reduced, confirming Stat6 as central mediator of IL-4 biological responses.\",\n      \"method\": \"Gene targeting/knockout mouse, flow cytometry, proliferation assays, parasite infection model\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — independent knockout mouse from separate lab, multiple orthogonal phenotypic readouts, replicates findings of Kaplan et al. 1996\",\n      \"pmids\": [\"8602263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"IL-13-mediated macrophage functions (morphologic changes and MHC class II upregulation) are abolished in STAT6-deficient mice, demonstrating that IL-13 signals through the same STAT6 pathway as IL-4.\",\n      \"method\": \"STAT6-knockout mouse, macrophage functional assays, flow cytometry\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with defined cellular phenotype, establishes shared pathway for IL-4 and IL-13 via STAT6\",\n      \"pmids\": [\"8871614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"STAT6 and NF-κB directly bind each other in vitro and in vivo (GST pulldown and co-immunoprecipitation); tyrosine-phosphorylated STAT6 and NF-κB bind cooperatively to DNA containing both cognate sites and synergistically activate IL-4-induced transcription.\",\n      \"method\": \"GST pulldown, co-immunoprecipitation, EMSA, luciferase reporter assay\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and in vitro pulldown plus functional reporter assay in two cell systems, single lab\",\n      \"pmids\": [\"9584180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"p300/CBP is required for STAT6-mediated transcriptional induction by IL-4; the STAT6 transactivation domain interacts with a C-terminal region of CBP (aa 1850–2176); E1A represses IL-4-induced STAT6 transcription through p300/CBP sequestration; co-immunoprecipitation confirmed endogenous STAT6–CBP complex.\",\n      \"method\": \"Two-hybrid assay, co-immunoprecipitation, E1A repression, luciferase reporter, GAL4 fusion assay\",\n      \"journal\": \"Nucleic Acids Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, two-hybrid, functional reporter, E1A mutants), single lab\",\n      \"pmids\": [\"10373589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"STAT6 suppresses STAT1-dependent transcription by a mechanism that does not require STAT6 DNA-binding to N4 sites (a H415A mutation that reduces N4 affinity retains full suppression of STAT1/IFNγ-driven transcription); suppression of NF-κB-dependent transcription requires both the STAT6 transactivation domain and STAT6 DNA binding to N4 sites; both mechanisms require the transactivation domain and likely involve sequestration of distinct coactivators.\",\n      \"method\": \"Transient transfection of STAT6 deletion/point mutants in STAT6-deficient HEK293 cells, luciferase reporter assay\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean STAT6-deficient cell reconstitution with mutagenesis, single lab, single method set\",\n      \"pmids\": [\"10982806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IL-4 induces phosphorylation of STAT6 on multiple serines within the transactivation domain (residues 719–789); serine phosphorylation does not require tyrosine 641 phosphorylation; PI3K, PKC, and MAPK pathways are not required, suggesting a novel kinase pathway.\",\n      \"method\": \"Phosphoamino acid analysis, 2D phosphopeptide mapping, STAT6 deletion/point mutants, kinase inhibitors\",\n      \"journal\": \"Molecular Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — biochemical phosphopeptide mapping with mutagenesis, single lab\",\n      \"pmids\": [\"11164892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"IL-4-induced STAT6 blocks NF-κB DNA binding and nuclear translocation, thereby inhibiting osteoclastogenesis; exogenously added STAT6 protein directly inhibits NF-κB/DNA interaction; IL-4 fails to block osteoclastogenesis in STAT6−/− mice but this is restored by exogenous STAT6.\",\n      \"method\": \"STAT6-knockout mouse osteoclast differentiation assay, EMSA competition, exogenous STAT6 protein addition\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout rescue experiment plus in vitro EMSA, multiple orthogonal approaches, single lab\",\n      \"pmids\": [\"11390419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Protein phosphatase 2A (PP2A) inhibition induces serine phosphorylation of STAT6 and severely inhibits STAT6 DNA binding, acting downstream of JAK kinases in IL-4 signaling; PP2A does not affect IL-4-induced tyrosine phosphorylation of JAK1 or STAT6.\",\n      \"method\": \"PP2A inhibitor (okadaic acid), EMSA, Western blot for phospho-STAT6\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological inhibitor plus biochemical assays, single lab, single method approach\",\n      \"pmids\": [\"12426308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"In mast cells, IL-4 induces nuclear translocation of full-length STAT6 followed by cleavage by a nuclear serine-family protease, generating a C-terminally truncated STAT6 isoform with preferential DNA-binding access; STAT6 chromatin immunoprecipitation identified IL-4-responsive target genes in mast cells including the IL-4 gene itself.\",\n      \"method\": \"Western blot, nuclear fractionation, serine protease inhibitors, chromatin immunoprecipitation\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — biochemical fractionation and ChIP with protease inhibitor experiments, single lab\",\n      \"pmids\": [\"12244176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Methylation of STAT6 on Arg27 is required for optimal IL-4-dependent STAT6 tyrosine phosphorylation, nuclear translocation, and DNA-binding activity; Arg27Ala mutant STAT6 and methylation inhibitors markedly diminish all three activities.\",\n      \"method\": \"STAT6 point mutagenesis (Arg27Ala), methylation inhibitors, Western blot, EMSA, nuclear fractionation\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis plus pharmacological inhibitors with multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"15153491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PKCζ interacts with and phosphorylates JAK1; PKCζ deficiency ablates Stat6 tyrosine phosphorylation and JAK1 activation in IL-4-stimulated fibroblasts and liver, placing PKCζ upstream of JAK1 in the IL-4/Stat6 pathway.\",\n      \"method\": \"PKCζ-knockout mouse, co-immunoprecipitation, kinase assay, Western blot for phospho-STAT6/JAK1\",\n      \"journal\": \"EMBO Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout combined with co-IP and in vitro kinase assay, multiple orthogonal readouts\",\n      \"pmids\": [\"15526032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IFN-γ suppresses STAT6 phosphorylation in differentiated Th1 cells by impairing STAT6 recruitment to the phosphorylated IL-4 receptor, without reducing IL-4R expression or JAK1/JAK3 phosphorylation; pulldown with phospho-IL-4R/GST fusion confirmed reduced STAT6 binding in WT vs. IFNGR−/− Th1 cells.\",\n      \"method\": \"IFNGR-knockout mouse T cells, GST pulldown of STAT6 to phospho-IL-4R, Western blot\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic model with GST pulldown, single lab, single biochemical approach\",\n      \"pmids\": [\"15661890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RNA helicase A (RHA) is a component of the STAT6 transcription complex; RHA does not directly interact with STAT6 but is bridged through the coactivator p100, forming a ternary STAT6–p100–RHA complex; p100-mediated RHA recruitment enhances STAT6 binding to the IgE promoter and IL-4-induced transcription.\",\n      \"method\": \"Co-immunoprecipitation, in vitro pulldown, chromatin immunoprecipitation, RNAi knockdown, luciferase reporter\",\n      \"journal\": \"Nucleic Acids Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, ChIP, RNAi, reporter), single lab\",\n      \"pmids\": [\"16914450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CoaSt6 (collaborator of STAT6) possesses PARP enzymatic activity that auto-ADP-ribosylates itself and modifies p100; a catalytically inactive CoaSt6 mutant fails to enhance STAT6-mediated transcription; chemical PARP inhibition blocks IL-4-dependent target gene transcription in vivo.\",\n      \"method\": \"PARP activity assay, CoaSt6 catalytic mutant, PARP inhibitors, luciferase reporter, chromatin immunoprecipitation\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with mutagenesis plus pharmacological inhibition and in-cell reporter, single lab\",\n      \"pmids\": [\"17478423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"IL-4-Stat6 signaling induces expression of tristetraprolin (TTP), an ARE-binding mRNA destabilizing protein, in mast cells; TTP then promotes decay of TNF-α mRNA in an AU-rich element-dependent manner; RNAi depletion of TTP prevents IL-4-mediated TNF-α down-regulation; this effect is absent in Stat6-deficient mice.\",\n      \"method\": \"Stat6-knockout mouse, RNAi, TNF-α mRNA stability assay, ELISA, peritoneal injection model\",\n      \"journal\": \"Journal of Experimental Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout plus RNAi rescue with molecular mechanism (mRNA stability), multiple orthogonal methods\",\n      \"pmids\": [\"14638848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A gain-of-function STAT6 mutant (STAT6VT) carrying two amino acid changes in the SH2 domain undergoes IL-4-independent tyrosine phosphorylation, dimerization, DNA binding, and transcriptional activation; phosphorylation is mediated by a non-IL-4/non-JAK1/JAK3 kinase in U4A fibroblasts.\",\n      \"method\": \"STAT6 mutagenesis, transfection in JAK1/JAK3-deficient U4A cells, EMSA, reporter assay, Western blot\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — gain-of-function mutagenesis in defined kinase-deficient cell background, multiple readouts, single lab\",\n      \"pmids\": [\"10747856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IFN-α activates Stat6 in B cells and induces formation of novel Stat2:Stat6 complexes (including a STAT2–STAT6–p48 ISGF3-like complex); this activation is cell-type specific, occurring predominantly in B cells.\",\n      \"method\": \"Western blot for phospho-STAT6, co-immunoprecipitation of STAT2:STAT6 complexes, cell line comparison\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and phospho-Western in primary B cells and B cell lines, single lab\",\n      \"pmids\": [\"10490982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The glucocorticoid receptor (GR) physically associates with STAT6 in T lymphocytes; GC suppress STAT6-dependent transcription without affecting STAT6 DNA binding; STAT6 overexpression enhances IL-4-mediated inhibition of GC-induced MMTV transactivation.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assay, EMSA in CTLL-2 cells\",\n      \"journal\": \"FEBS Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP with functional reporter, single lab, single cell line\",\n      \"pmids\": [\"11150515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The E3 ubiquitin ligase Grail interacts with STAT6, ubiquitinates it, and targets it for degradation, creating a negative feedback loop in Th2 cells; Grail deficiency results in increased STAT6 and IL-4 receptor α expression and enhanced Th2 effector cytokine production; Grail expression itself depends on IL-4/STAT6/GATA3 signaling.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, Grail-knockout mouse, Western blot, allergy model\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout plus ubiquitination assay plus Co-IP, multiple orthogonal methods, functional in vivo validation\",\n      \"pmids\": [\"25145352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structures of phosphorylated STAT6 core fragment (homodimer) alone and bound to N3 and N4 DNA sites reveal a dramatic conformational change upon DNA binding; H415 in the DNA-binding domain discriminates N4 from N3 sites; H415N mutation decreases N4 affinity and increases N3 affinity both in vitro and in vivo.\",\n      \"method\": \"X-ray crystallography, molecular dynamics simulation, SAXS, point mutagenesis, DNA binding assay\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with mutagenesis and biophysical validation by three orthogonal methods\",\n      \"pmids\": [\"27803324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Follicular lymphoma-associated STAT6 mutations (hotspot D419) are activating; they increase transactivation in reporter assays, enhance IL-4-induced target gene expression, and facilitate nuclear residency of STAT6 independently of IL-4-induced Y641 phosphorylation; structural modeling places most mutations at the STAT6–DNA interface.\",\n      \"method\": \"Luciferase reporter assay, stable STAT6 transfection in lymphoma cell lines, nuclear fractionation, whole-exome sequencing, structural modeling\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple functional assays (reporter, target gene expression, nuclear fractionation) on primary patient material and cell lines\",\n      \"pmids\": [\"25428220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"IL-4-activated STAT6 is required for direct transcriptional repression of a large set of genes during alternative macrophage polarization; repression is associated with decreased lineage-determining TF, p300, and RNA Pol II binding, reduced enhancer RNA, H3K27ac, and chromatin accessibility; STAT6 repressor function is HDAC3-dependent on a subset of genes; STAT6-repressed enhancers overlap the NF-κB p65 cistrome and show decreased LPS responsiveness after IL-4 stimulus.\",\n      \"method\": \"ChIP-seq, ATAC-seq, enhancer RNA profiling, HDAC3 inhibition, STAT6-knockout macrophages, in vivo polarization\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genome-wide chromatin assays (ChIP-seq, ATAC-seq) with genetic knockout and pharmacological validation, multiple orthogonal methods\",\n      \"pmids\": [\"29343442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"JAK3-STAT6 pathway activation downstream of IL-4 is required for TET2-dependent DNA demethylation at dendritic-cell-specific loci during monocyte-to-DC differentiation; a constitutively active STAT6 bypasses upstream IL-4 signaling and instructs DC-specific demethylation.\",\n      \"method\": \"DNA methylome profiling, TET2 knockdown, JAK3 inhibitor, constitutively active STAT6 expression\",\n      \"journal\": \"Genome Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide methylome with genetic and pharmacological perturbations plus constitutively active STAT6 rescue, multiple orthogonal methods\",\n      \"pmids\": [\"26758199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"STAT6 deficiency in microglia/macrophages reduces efferocytosis of dead neurons, increases inflammatory gene expression, and enlarges infarct volume after experimental stroke; decreased Arginase 1 (Arg1) expression in STAT6−/− microglia/macrophages is responsible for impaired efferocytosis; adoptive transfer of WT macrophages rescues efferocytosis in STAT6-KO mice.\",\n      \"method\": \"STAT6-knockout mouse, bone marrow chimeras, microglia/macrophage-neuron co-culture, adoptive macrophage transfer, flow cytometry\",\n      \"journal\": \"JCI Insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with BM chimera and adoptive transfer rescue, multiple orthogonal in vivo and in vitro experiments\",\n      \"pmids\": [\"31619589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"STAT6 activation downstream of IL-4 or TSG6 signaling drives Gas6 expression in alveolar macrophages; Gas6 expression is required for efferocytosis of apoptotic neutrophils; Gas6-depleted macrophages fail to clear PMNs in LPS-challenged lungs.\",\n      \"method\": \"In vitro macrophage priming, adoptive macrophage transfer, Gas6 knockdown, STAT6 inhibition, co-culture efferocytosis assay\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic in vitro and in vivo experiments with adoptive transfer and gene knockdown, multiple orthogonal methods\",\n      \"pmids\": [\"31363052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A stapled helical peptide targeting NCOA1 disrupts the NCOA1/STAT6 protein-protein interaction and represses STAT6-mediated transcription; crystal structure of stapled peptide bound to NCOA1 was solved.\",\n      \"method\": \"Crystal structure of NCOA1–stapled peptide complex, co-immunoprecipitation, luciferase reporter assay\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure plus functional disruption assay, single lab, multiple methods\",\n      \"pmids\": [\"29090910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRAF6 stabilizes STAT6 protein by binding STAT6 via its TRAF6 C domain and reducing K48-linked (degradative) ubiquitination of STAT6; TRAF6 promotes K63-linked ubiquitination of STAT6; TRAF6 E3 ligase activity is dispensable for STAT6 stabilization.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay with K48/K63 linkage-specific antibodies, TRAF6 overexpression/knockout, Western blot\",\n      \"journal\": \"Molecular Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and ubiquitination assay, single lab, mechanistic follow-up limited\",\n      \"pmids\": [\"33017719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRAF3 promotes STAT6 ubiquitination (at K450 and K129 residues) and transcriptional activity; site mutation of K450 abolishes TRAF3-mediated STAT6 activation; TRAF3 deficiency reduces K450 ubiquitination and impairs IL-4-induced M2 macrophage polarization.\",\n      \"method\": \"Quantitative ubiquitomics, ubiquitination assay, luciferase reporter, STAT6 site mutagenesis, TRAF3-knockout macrophages\",\n      \"journal\": \"Cell Death and Differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-specific mutagenesis plus quantitative ubiquitomics and reporter assay, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"37474750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"STAT6 competitively binds CREB-binding protein (CBP), inhibiting CBP-mediated P53 acetylation; reduced P53 acetylation transcriptionally restores SLC7A11 expression, thereby suppressing ferroptosis in lung epithelial cells; lung-specific STAT6 depletion exacerbates ferroptosis and ALI.\",\n      \"method\": \"Co-immunoprecipitation (STAT6–CBP), P53 acetylation assay, ChIP for P53 on SLC7A11 promoter, lung-specific STAT6 knockout mouse, ferrostatin-1 rescue\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and ChIP with genetic knockout, single lab, mechanistic pathway partially established\",\n      \"pmids\": [\"35668064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"STAT6 transcriptionally inhibits PPARα expression through a SIE (sis-inducible element) in the PPARα promoter, reducing fatty acid oxidation-related gene expression and promoting lipid accumulation in renal tubular cells; STAT6 inhibition or tubular-specific depletion restores FAO and attenuates renal fibrosis.\",\n      \"method\": \"ChIP assay of STAT6 on PPARα promoter, tubular-specific STAT6-knockout mouse, STAT6 inhibitor, gene expression profiling\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP with genetic and pharmacological STAT6 modulation, single lab\",\n      \"pmids\": [\"35046382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A gain-of-function STAT6 missense variant (p.D419N) increases transcriptional activity independent of IL-4 stimulation, promotes nuclear localization of STAT6 without phosphorylation at baseline, and causes hyperphosphorylation upon IL-4 stimulation; knock-in mice develop spontaneous dermatitis with eosinophil infiltration and elevated IgE.\",\n      \"method\": \"Luciferase reporter, nuclear fractionation, knock-in mouse model, Western blot\",\n      \"journal\": \"Journal of Allergy and Clinical Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain-of-function mutagenesis validated in patient cells and knock-in mouse with multiple functional readouts\",\n      \"pmids\": [\"36538978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A gain-of-function STAT6 mutation (p.E372K in the DNA-binding domain) augments both basal and cytokine-induced STAT6 phosphorylation without altering dephosphorylation kinetics; JAK1/2 inhibitor ruxolitinib reverses the STAT6 hyperresponsiveness, demonstrating the mutation acts upstream of or at the JAK-STAT6 interface.\",\n      \"method\": \"Western blot of patient lymphocytes, EMSA, immunofluorescence, luciferase assay, JAK inhibitor treatment\",\n      \"journal\": \"Journal of Allergy and Clinical Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple functional assays in patient cells with pharmacological rescue, orthogonal methods\",\n      \"pmids\": [\"36758835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IL-4 inhibits melanogenesis in normal human melanocytes through JAK2-STAT6 signaling; IL-4 increases STAT6 phosphorylation and downregulates MITF and dopachrome tautomerase; JAK2 inhibitor AG490 or STAT6 siRNA blocks IL-4-induced melanogenesis suppression.\",\n      \"method\": \"JAK2 inhibitor, STAT6 siRNA knockdown, Western blot for pSTAT6, gene expression analysis\",\n      \"journal\": \"Journal of Investigative Dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological inhibitor plus siRNA knockdown, single lab, primary human cells\",\n      \"pmids\": [\"22992805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IL-4-activated STAT6 is required for Th9 development by repressing T-bet and Foxp3 expression and inducing IRF4; STAT6 activation is independent of TGF-β-induced PU.1 (Sfpi1); these mechanisms define the transcription factor network balancing IL-9 production.\",\n      \"method\": \"STAT6-knockout mouse Th differentiation assay, retroviral STAT6/IRF4 expression, intracellular cytokine staining\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with retroviral rescue and multiple transcription factor readouts, single lab\",\n      \"pmids\": [\"22180613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"STAT6-STAT1 axis regulates OC-STAMP and DC-STAMP expression governing macrophage cell-cell fusion (FBGC formation); STAT6 deficiency increases STAT1 activation and inhibits fusion; STAT1 deficiency or co-expression of OC-STAMP/DC-STAMP is sufficient to induce fusion independently of IL-4.\",\n      \"method\": \"STAT6-knockout and STAT1-knockout mouse macrophage fusion assay, OC-STAMP/DC-STAMP co-expression, Western blot\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic knockouts with defined cellular phenotype, single lab, mechanistic epistasis established\",\n      \"pmids\": [\"22865856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A germline STAT6 gain-of-function variant (p.Glu377Lys, DNA-binding domain) displays strong nuclear localization preference, increased DNA-binding affinity, and spontaneous transcriptional activity without cytokine stimulation; gastric organoids from the patient show constitutive STAT6 downstream signaling.\",\n      \"method\": \"EMSA, immunofluorescence, luciferase assay, Western blot, patient-derived gastric organoids\",\n      \"journal\": \"Journal of Allergy and Clinical Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (EMSA, imaging, reporter, organoids) in patient-derived primary material\",\n      \"pmids\": [\"36216080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PARP14 is a transcriptional co-activator and direct target of STAT6; activating STAT6 mutations (within the DNA-binding domain) bind the PARP14 promoter (shown by qChIP), increase IL-4-induced transactivation at the PARP14 promoter, and create a self-reinforcing STAT6–PARP14 regulatory circuit; PARP14 knockdown or PARP inhibition abrogates STAT6-mutant gain-of-function.\",\n      \"method\": \"qChIP of STAT6 on PARP14 promoter, luciferase reporter, PARP14 siRNA, PARP inhibitor, RNA sequencing\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reporter, and functional rescue experiments with multiple orthogonal methods, single lab\",\n      \"pmids\": [\"35851155\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"STAT6 is a latent cytoplasmic transcription factor activated primarily by IL-4 and IL-13: upon receptor engagement, JAK kinases (including JAK1 and JAK3) phosphorylate STAT6 on Tyr641, a step facilitated by prior Arg27 methylation and regulated by PKCζ-dependent JAK1 phosphorylation, PP2A, and IFN-γ-mediated impairment of STAT6 recruitment to the IL-4 receptor; activated STAT6 dimerizes, translocates to the nucleus (a step that can also occur via constitutively activating mutations in the SH2 or DNA-binding domains), and binds N4-type GAS elements—preferentially over N3 sites through a unique H415 residue—as revealed by crystal structures; in the nucleus STAT6 recruits coactivators p300/CBP (at a distinct CBP C-terminal region), NCOA1, the p100–RNA helicase A complex, and the PARP-active cofactor CoaSt6/PARP14 to drive transcription of Th2-associated genes (including CCL17, CCL22, Gas6, Arg1, IL-31RA, TARC, and eotaxin-1); STAT6 simultaneously represses inflammatory enhancers in an HDAC3-dependent manner, inhibits NF-κB DNA binding, and suppresses PPARα-driven fatty acid oxidation via a SIE element; its activity is negatively regulated by the E3 ligase Grail (which ubiquitinates STAT6 for degradation) and positively stabilized by TRAF6 (which reduces K48-ubiquitination) and TRAF3 (which promotes activating K450 ubiquitination); in mast cells a nuclear serine protease cleaves full-length STAT6 to a truncated isoform; and somatic or germline gain-of-function mutations in the DNA-binding domain cause constitutive nuclear residency and ligand-independent transcriptional activation, driving allergic disease and lymphomagenesis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"STAT6 is a latent cytoplasmic transcription factor that serves as the central effector of IL-4 and IL-13 signaling, driving Th2-associated gene programs, alternative macrophage polarization, and humoral responses [#0, #1, #3]. It was cloned as an IL-4-induced tyrosine-phosphorylated DNA-binding protein whose intracellular receptor coupling and dimerization map to the same functional domain [#0], and genetic ablation in mice abolishes IL-4/IL-13-driven CD23 and MHC class II upregulation, B-cell proliferation, IgE/IgG1 class switching, Th2 differentiation, and IL-13-mediated macrophage activation [#1, #2, #3]. Receptor-proximal activation requires JAK1, which is itself phosphorylated by upstream PKC\\u03b6, and is potentiated by Arg27 methylation that licenses optimal tyrosine phosphorylation, nuclear translocation, and DNA binding [#11, #12]. Activated STAT6 dimerizes and engages N4-type GAS elements with preference over N3 sites through a discriminating H415 residue, as resolved by crystal structures showing a large DNA-binding conformational change [#21]. In the nucleus STAT6 recruits coactivators p300/CBP, NCOA1, the bridging p100\\u2013RNA helicase A complex, and the PARP-active cofactor CoaSt6/PARP14 to activate target genes, while it also represses inflammatory enhancers overlapping the NF-\\u03baB p65 cistrome in an HDAC3-dependent manner and directly blocks NF-\\u03baB DNA binding [#5, #14, #15, #23, #8]. Through these outputs STAT6 instructs Arg1- and Gas6-dependent macrophage efferocytosis, monocyte-to-DC demethylation, and Th9 differentiation [#25, #26, #24, #35]. STAT6 abundance and activity are tuned by ubiquitination: the E3 ligase Grail targets it for degradation, whereas TRAF6 reduces K48-linked degradative ubiquitination and TRAF3 promotes activating K450 ubiquitination [#20, #28, #29]. Gain-of-function mutations in the SH2 and DNA-binding domains confer ligand-independent nuclear residency and constitutive transcription, causing germline allergic disease with eosinophilia and elevated IgE and driving follicular lymphomagenesis, with mutant activity sustained by a self-reinforcing STAT6\\u2013PARP14 circuit [#17, #22, #32, #37, #38].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established the molecular identity of the IL-4-induced DNA-binding activity, defining STAT6 as a receptor-coupled transcription factor and the entry point of the entire pathway.\",\n      \"evidence\": \"Protein purification, gene cloning, and phosphopeptide inhibition of receptor coupling\",\n      \"pmids\": [\"8085155\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify activating kinases\", \"No nuclear target genes defined at this stage\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined STAT6 as genetically essential and non-redundant for IL-4 and IL-13 biology, converting a biochemical activity into a defined physiological pathway.\",\n      \"evidence\": \"Independent STAT6-knockout mice with B-cell, T-cell, IgE, Th2, and macrophage readouts\",\n      \"pmids\": [\"8624821\", \"8602263\", \"8871614\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Knockouts did not resolve direct vs indirect target genes\", \"Mechanism of IL-4/IL-13 pathway convergence not molecularly dissected\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showed STAT6 acts not only as an activator but as a repressor of STAT1/IFN\\u03b3 and NF-\\u03baB transcription, and that gain-of-function SH2 mutants activate independently of IL-4/JAK1/JAK3, foreshadowing constitutive disease alleles.\",\n      \"evidence\": \"Mutant reconstitution in STAT6-deficient and JAK-deficient cells with reporter and EMSA assays\",\n      \"pmids\": [\"10982806\", \"10747856\", \"11150515\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the non-JAK kinase phosphorylating STAT6VT not determined\", \"Coactivator-sequestration model of repression not directly proven\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated direct STAT6\\u2013NF-\\u03baB cross-regulation, with STAT6 protein blocking NF-\\u03baB DNA binding and nuclear translocation to suppress osteoclastogenesis, extending STAT6 beyond Th2 gene induction.\",\n      \"evidence\": \"Reciprocal Co-IP, EMSA cooperativity/competition, and knockout rescue with exogenous STAT6\",\n      \"pmids\": [\"9584180\", \"11390419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of STAT6\\u2013NF-\\u03baB contact not resolved\", \"In vivo balance of cooperative vs antagonistic NF-\\u03baB outcomes unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Mapped upstream and post-translational control of activation, placing PKC\\u03b6 above JAK1 and identifying Arg27 methylation as a licensing modification for tyrosine phosphorylation and nuclear entry.\",\n      \"evidence\": \"PKC\\u03b6-knockout mice with kinase assays, and Arg27Ala mutagenesis with methylation inhibitors\",\n      \"pmids\": [\"15526032\", \"15153491\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Arg27 methyltransferase not identified\", \"Quantitative ordering of methylation relative to receptor engagement not established\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Resolved the composition of the STAT6 nuclear coactivator complex, showing RNA helicase A is recruited via the p100 bridge and enhances IgE promoter occupancy and transcription.\",\n      \"evidence\": \"Co-IP, in vitro pulldown, ChIP, RNAi, and reporter assays\",\n      \"pmids\": [\"16914450\", \"10373589\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry of the STAT6\\u2013p100\\u2013RHA complex undefined\", \"Genome-wide scope of RHA dependence not established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified an enzymatic coactivator arm, CoaSt6/PARP14 ADP-ribosylation activity, required for STAT6-driven transcription, linking a catalytic modification to target gene output.\",\n      \"evidence\": \"PARP activity assay with catalytic-dead mutant, PARP inhibitors, reporter, and ChIP\",\n      \"pmids\": [\"17478423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ADP-ribosylation targets within the complex beyond p100 not fully mapped\", \"In vivo relevance to physiological Th2 genes only partially defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided the structural mechanism of DNA-site selectivity, showing H415 discriminates N4 from N3 GAS elements through a major conformational change on binding.\",\n      \"evidence\": \"X-ray crystallography of phospho-STAT6 dimer with N3/N4 DNA, SAXS, MD, and H415 mutagenesis\",\n      \"pmids\": [\"27803324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length STAT6 (with transactivation and N-domains) not crystallized\", \"Structure of coactivator-bound complexes not solved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established STAT6 as a genome-scale direct transcriptional repressor in alternatively activated macrophages, acting through HDAC3 and decommissioning NF-\\u03baB-overlapping inflammatory enhancers.\",\n      \"evidence\": \"ChIP-seq, ATAC-seq, eRNA profiling, HDAC3 inhibition, and STAT6-knockout macrophages\",\n      \"pmids\": [\"29343442\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of HDAC3 recruitment by STAT6 not defined\", \"Determinants of activated vs repressed locus choice unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected STAT6 transcriptional output to functional macrophage programs, showing Arg1- and Gas6-dependent efferocytosis that limits tissue injury.\",\n      \"evidence\": \"STAT6-knockout mice, bone marrow chimeras, adoptive transfer, gene knockdown, and co-culture efferocytosis\",\n      \"pmids\": [\"31619589\", \"31363052\", \"26758199\", \"22180613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect STAT6 control of Arg1/Gas6 loci not fully dissected in every tissue\", \"Crosstalk with other AAM transcription factors incompletely mapped\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined ubiquitin-based control of STAT6 stability and activity, with Grail driving degradation, TRAF6 antagonizing degradative K48 chains, and TRAF3 installing activating K450 ubiquitin.\",\n      \"evidence\": \"Co-IP, linkage-specific ubiquitination assays, site mutagenesis, and E3-ligase knockout macrophages/mice\",\n      \"pmids\": [\"25145352\", \"33017719\", \"37474750\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Deubiquitinases counteracting these E3s not identified\", \"Interplay/ordering of competing ubiquitin marks on the same molecule unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established gain-of-function STAT6 alleles as drivers of human disease, with SH2 and DNA-binding-domain mutations conferring ligand-independent nuclear residency and constitutive transcription in allergy and lymphoma, sustained by a STAT6\\u2013PARP14 feed-forward loop and reversible by JAK inhibition.\",\n      \"evidence\": \"Reporter assays, nuclear fractionation, EMSA, patient cells/organoids, knock-in mice, qChIP, PARP14 knockdown, and ruxolitinib treatment\",\n      \"pmids\": [\"25428220\", \"36538978\", \"36758835\", \"36216080\", \"35851155\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype determinants separating allergic vs oncogenic outcomes unclear\", \"Whether PARP14 circuit is therapeutically tractable in patients not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The kinase responsible for ligand-independent phosphorylation of STAT6 gain-of-function mutants and the identity of the Arg27 methyltransferase and STAT6-cleaving mast-cell protease remain undefined.\",\n      \"evidence\": \"Not yet addressed in the available corpus\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Non-JAK kinase acting on constitutive STAT6 mutants not identified\", \"Physiological role of the truncated mast-cell STAT6 isoform unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 22, 23, 38]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 21, 37]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [21]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 11]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [11, 22, 32, 37]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 12, 21]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 14, 23, 38]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 3, 23, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [22, 32, 37]}\n    ],\n    \"complexes\": [\n      \"STAT6\\u2013p100\\u2013RNA helicase A complex\",\n      \"STAT2\\u2013STAT6\\u2013p48 (ISGF3-like) complex\"\n    ],\n    \"partners\": [\n      \"CBP/p300\",\n      \"NCOA1\",\n      \"PARP14\",\n      \"NFKB1\",\n      \"JAK1\",\n      \"TRAF6\",\n      \"TRAF3\",\n      \"RBCK1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}